Clinical Trials

Our lead product, EP-100, is an oncolytic peptide that seeks and destroys cancer cells that express receptors for luteinizing hormone releasing hormone (LHRH). Many cancers including ovarian, breast, prostate, pancreatic, skin (melanoma) and non-Hodgkin’s lymphoma overexpress LHRH receptor.

EP-100 has completed Phase 2 clinical trial in patients with advanced ovarian cancer.  Additional clinical trials are planned.